Last reviewed · How we verify
Chronic idiopathic thrombocytopenic purpura
Approved treatments
- Promacta · Novartis
Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow. - Tavalisse · Rigel Pharms
Tavalisse works by blocking the activity of the FLT3 enzyme, which is involved in the production of platelets. - Nplate · Amgen
Nplate works by binding to the thrombopoietin receptor to stimulate platelet production. - Nplate · Nantes University Hospital
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Chronic idiopathic thrombocytopenic purpura patent landscape — cliff calendar, originator estates, attackable patents
- Chronic idiopathic thrombocytopenic purpura treatment landscape brief
- Chronic idiopathic thrombocytopenic purpura treatment updates RSS
Frequently asked questions about Chronic idiopathic thrombocytopenic purpura
What drugs treat Chronic idiopathic thrombocytopenic purpura?
Tracked treatments include Promacta, Tavalisse, Nplate.
What is the treatment for Chronic idiopathic thrombocytopenic purpura?
Standard treatment for Chronic idiopathic thrombocytopenic purpura includes Promacta, Tavalisse, Nplate. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Chronic idiopathic thrombocytopenic purpura patent cliff · Chronic idiopathic thrombocytopenic purpura CI report
- Treatment: Promacta · Novartis
- Treatment: Tavalisse · Rigel Pharms
- Treatment: Nplate · Amgen
- Treatment: Nplate · Nantes University Hospital
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing